Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2) antagonist with potential antineoplastic activity owing to increase in p53 activity through interruption of the MDM2‐p53 interaction. This phase I, dose‐escalating study assessed the safety, tolerability, efficacy, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Shunji, Fujiwara, Yutaka, Nakano, Kenji, Shimizu, Toshio, Tomomatsu, Junichi, Koyama, Takafumi, Ogura, Mariko, Tachibana, Masaya, Kakurai, Yasuyuki, Yamashita, Tomonari, Sakajiri, Sakura, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177775/
https://www.ncbi.nlm.nih.gov/pubmed/33686772
http://dx.doi.org/10.1111/cas.14875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177775/
https://www.ncbi.nlm.nih.gov/pubmed/33686772
http://dx.doi.org/10.1111/cas.14875

Ejemplares similares